NCT07278856
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
At risk: Primary completion moved at least 8 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Mar 31, 2027 to Dec 10, 2027
- Eligibility criteria expanded, about 68 words
- Secondary endpoints: details revised at 3 of 8 entries
- Study description revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 27, 2026 to Dec 16, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Maximum tolerated dose (MTD) of ruxolitinib when given in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy
Timeframe: Prior to cycle 2 day 1 (cycle length = 21 days)
Incidence of adverse events
Timeframe: Up to 30 days after last dose of treatment
Secondary (8)
Rate of ruxolitinib discontinuation due to toxicity while receiving ruxolitinib with CHOP therapy (Part A)
Complete response (CR) rate (Part A)
Overall response rate (Part A)
Patient-reported outcomes (Part A)
Rate of ruxolitinib discontinuation due to toxicity while receiving ruxolitinib maintenance monotherapy following ruxolitinib with CHOP (Part B)
Show 3 moreShow less
Rate of conversion from partial response to CR (Part B)
Patient-reported outcomes (Part B) PROMIS
Patient-reported outcomes (Part B) FACT-Item GP5
Arms and interventions
Treatment (ruxolitinib, CHOP)Experimental
See Detailed Description
Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography, Multigated Acquisition Scan
Drugs: Cyclophosphamide, Doxorubicin, Prednisone, Ruxolitinib Phosphate, Vincristine
Biologicals: Filgrastim, Pegfilgrastim
Other: Fludeoxyglucose F-18, Questionnaire Administration
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States